

2021/11/16

ASCO Gastrointestinal Cancer Symposium 2022(ASCO GI)
に JACCRO から 5 演題が採択されました。

Jan 20-22, 2022
Moscone West, San Francisco

- **Rapid Abstract Session A (Short oral):** Cancers of the Esophagus and Stomach, 1/20/2022 11:15 AM-12:00PM Abstract Number: 245 **Abstract Title: Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).** Top author: 砂川 優 先生(聖マリアンナ医科大学)
- **Poster Session C:** Cancers of the Colon, Rectum, and Anus Abstract Number: 109 **Abstract Title: Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: the subgroup-analysis of DEEPER trial (JACCRO CC-13).** Top author: 佐竹 悠良(神戸市立医療センター中央市民病院)
- **Poster Session C:** Cancers of the Colon, Rectum, and Anus Abstract Number: 112 **Abstract Title: A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16.** Top author: 中村 将人 先生(相澤病院)
- **Poster Session A:** Cancers of the Esophagus and Stomach and Other GI Cancers Abstract Number: 306 **Abstract Title: A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX trial (JACCRO GC-09).** Top author: 鈴木 崇久 先生(呉医療センター)
- **Trials in Progress Poster Session C:** Cancers of the Colon, Rectum, and Anus Abstract Number: TPS230 **Abstract Title: An observational study to evaluate RAS mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17).** Top author: 伊澤 直樹 先生(聖マリアンナ医科大学)

今回も Hybrid ですが皆様の参加をお待ちしています。